Mastectomy for Malignancy without CC/MCC DRG Reimbursement

DRG 583 applies to inpatient mastectomy for malignancy without Complication or Comorbidity or Major Complication or Comorbidity; it defines the clinical scope as surgical treatment of breast cancer without additional complicating conditions. Assignment to this Diagnosis-Related Group matters for inpatient reimbursement because it determines the prospective payment amount that Medicare provides for routine mastectomy hospitalizations.

DRG 583 Overview

DRG 583 covers inpatient admissions for mastectomy performed to treat breast malignancy when no Complication or Comorbidity and no Major Complication or Comorbidity are present. This Diagnosis-Related Group applies to surgical management of primary breast cancer and related perioperative care during a single inpatient stay. It matters for Medicare payment because cases assigned to this Diagnosis-Related Group receive a specific prospective payment that reflects expected resource use for straightforward mastectomy encounters. Accurate coding of diagnoses and procedures determines assignment to this Diagnosis-Related Group and the associated reimbursement.

Perioperative surgical technique and reconstruction outcomes: randomized or observational studies comparing different mastectomy approaches (skin-sparing, nipple-sparing, total mastectomy) and immediate breast reconstruction strategies (implant-based vs autologous tissue) in patients undergoing mastectomy for early-stage breast cancer without major comorbidities. These studies focus on short-term surgical metrics (operative time, blood loss, wound complications, reoperation), oncologic safety (margin status, local recurrence within early follow-up), and patient-reported cosmetic and quality-of-life outcomes. This research is relevant to surgeons, hospital administrators, and payers because surgical approach and reconstruction choices directly affect resource utilization, length of stay, complication rates, readmissions, and downstream costs for this DRG population.
Comparative effectiveness of perioperative care bundles and enhanced recovery protocols: trials and cohort studies testing ERAS pathways, antibiotic prophylaxis timing/duration, thromboembolism prevention regimens, and pain-management strategies (opioid-sparing multimodal analgesia) in otherwise healthy mastectomy patients without CC/MCC. These studies evaluate impacts on immediate postoperative recovery metrics — pain control, opioid consumption, time to ambulation, length of stay, and incidence of surgical site infection — and may stratify by age, BMI, or smoking status. Findings inform clinical pathways that can reduce complications and resource use, making them highly pertinent for clinicians optimizing care and for payers seeking to control costs and improve quality metrics for DRG 583 cases.
Post-discharge outcomes, surveillance, and rehabilitation studies: prospective registries and longitudinal cohort studies following patients after discharge to assess wound healing, lymphedema incidence, psychosocial outcomes, and adherence to adjuvant oncologic treatments in patients who had mastectomy for malignancy without significant comorbidity. Research in this area examines predictors of readmission, outpatient service utilization (wound care, physical therapy), and long-term functional and quality-of-life trajectories, often including interventions such as early physiotherapy or patient education to prevent lymphedema and improve recovery. This evidence is critical for care managers and payers because it identifies high-risk subgroups that may need targeted outpatient resources to prevent costly readmissions and to optimize longitudinal outcomes for patients classified under this DRG.

Perioperative surgical technique and reconstruction outcomes: randomized or observational studies comparing different mastectomy approaches (skin-sparing, nipple-sparing, total mastectomy) and immediate breast reconstruction strategies (implant-based vs autologous tissue) in patients undergoing mastectomy for early-stage breast cancer without major comorbidities. These studies focus on short-term surgical metrics (operative time, blood loss, wound complications, reoperation), oncologic safety (margin status, local recurrence within early follow-up), and patient-reported cosmetic and quality-of-life outcomes. This research is relevant to surgeons, hospital administrators, and payers because surgical approach and reconstruction choices directly affect resource utilization, length of stay, complication rates, readmissions, and downstream costs for this DRG population.
Comparative effectiveness of perioperative care bundles and enhanced recovery protocols: trials and cohort studies testing ERAS pathways, antibiotic prophylaxis timing/duration, thromboembolism prevention regimens, and pain-management strategies (opioid-sparing multimodal analgesia) in otherwise healthy mastectomy patients without CC/MCC. These studies evaluate impacts on immediate postoperative recovery metrics — pain control, opioid consumption, time to ambulation, length of stay, and incidence of surgical site infection — and may stratify by age, BMI, or smoking status. Findings inform clinical pathways that can reduce complications and resource use, making them highly pertinent for clinicians optimizing care and for payers seeking to control costs and improve quality metrics for DRG 583 cases.
Post-discharge outcomes, surveillance, and rehabilitation studies: prospective registries and longitudinal cohort studies following patients after discharge to assess wound healing, lymphedema incidence, psychosocial outcomes, and adherence to adjuvant oncologic treatments in patients who had mastectomy for malignancy without significant comorbidity. Research in this area examines predictors of readmission, outpatient service utilization (wound care, physical therapy), and long-term functional and quality-of-life trajectories, often including interventions such as early physiotherapy or patient education to prevent lymphedema and improve recovery. This evidence is critical for care managers and payers because it identifies high-risk subgroups that may need targeted outpatient resources to prevent costly readmissions and to optimize longitudinal outcomes for patients classified under this DRG.

OpenPayer

Summary & Overview

Mastectomy for Malignancy without CC/MCC: Inpatient Reimbursement Overview

DRG 583 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes